Clinical trials: Inadequate Response
Primary Biliary Cholangitis, Primary Biliary Cirrhosis
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy.
- Conditions
- Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis
- Trial name
- PRONTO-PBC (NCT04604652)
- Testing
- HTD1801 (BUDCA)
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Chronic Liver Disease, Hypovitaminosis
Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients
The purpose of this study is to determine how common low levels of magnesium are in patients with end stage liver disease. In addition, investigator is trying to determine if low levels of magnesium affect the release of…
- Trial name
- NCT00599352
- Testing
- magnesium
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rajib Bhattacharya, MD
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Human Immunodeficiency Virus
Improving Prognosis in HIV Infection
The primary objective of this study is to assess the safety of probiotics in cART-treated immunologic non-responder (INR) patients with chronic HIV infection.
- Trial name
- NCT02640625
- Testing
- Probiotic compound
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Major Depressive Disorder
A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of 10, 20, 40 and 60 mg oral PRAX-114 compared to placebo in the treatment of adults with MDD.
- Trial name
- NCT04969510
- Testing
- 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114
- Where
- 24 sites in United States, Australia
- Volunteers
- 110 people
- Sponsor
- Praxis Precision Medicines
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
This study includes two periods. In Period 1, Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice-daily oral LNK01001 Dose A or LNK01001 Dose B or a matching placebo for 12 weeks.
- Trial name
- NCT06099535
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Japanese Encephalitis
Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
IC51-319 is a single-arm, open-label study that investigates immune responses in subjects undergoing revaccination after receiving the subpotent batch of IXIARO JEV09L37 during primary immunization.
- Trial name
- NCT01559831
- Testing
- IXIARO
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Arthritis, Rheumatoid
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects who are methotrexate-inadequate responders (MTX-IR).
- Trial name
- NCT01554696
- Testing
- peficitinib, methotrexate
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 379 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Rheumatoid Arthritis
A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs
The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT02308163
- Testing
- Peficitinib, Etanercept
- Where
- 153 sites in Japan, South Korea and 1 more
- Volunteers
- 509 people
- Sponsor
- Astellas Pharma Inc
Active Polyarticular Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
The purpose of this study is to estimate Abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA
- Trial name
- NCT01844518
- Testing
- Abatacept
- Where
- 57 sites in United States, Argentina and 10 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Primary Biliary Cirrhosis
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion.
- Trial name
- NCT04956328
- Testing
- Obeticholic Acid Tablets, UDCA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT00810199
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 137 sites in United States, Brazil and 18 more
- Volunteers
- 556 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
This Phase IIIb, open-label, single-arm study will evaluate the safety, efficacy, and tolerability of SC tocilizumab (RoActemra/Actemra) in monotherapy or in combination with methotrexate or other non-biologic DMARDs in…
- Trial name
- NCT02046616
- Testing
- Tocilizumab, Methotrexate, Non-Biologic DMARDs
- Where
- 27 sites in Denmark, Finland and 2 more
- Volunteers
- 133 people
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie
Rheumatoid Arthritis
Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have…
- Trial name
- NCT02969044
- Testing
- PF-06651600
- Where
- 30 sites in United States, Bulgaria and 7 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
The purpose of this study is to investigate the safety and efficacy of multiple dose levels of the investigational product (study drug), IPI-145, in combination with methotrexate compared to methotrexate alone in subjects with…
- Trial name
- ASPIRA (NCT01851707)
- Testing
- IPI-145
- Where
- 64 sites in Bulgaria, Colombia and 9 more
- Volunteers
- 322 people
- Sponsor
- SecuraBio
Rheumatoid Arthritis
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
The purpose of this study is to investigate whether the drug BG00012 can improve the symptoms of rheumatoid arthritis (RA) in patients who are already taking methotrexate for RA, but who still suffer symptoms of RA.
- Trial name
- NCT00810836
- Testing
- BG00012
- Where
- 24 sites in Australia, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Biogen
Rheumatoid Arthritis
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
This prospective, multi-center, observational study will evaluate the efficacy and the safety of MabThera (rituximab) in participants with rheumatoid arthritis who have not responded or have been intolerant to a first anti-TNF…
- Trial name
- NCT01592292
- Testing
- Rituximab, Adalimumab, Etanercept
- Where
- 15 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche